Nitric Oxide Directly Promotes Vascular Endothelial Insulin Transport
Insulin resistance strongly associates with decreased nitric oxide (NO) bioavailability and endothelial dysfunction. In the vasculature, NO mediates multiple processes that affect insulin delivery, including dilating both resistance and terminal arterioles in skeletal muscle in vivo. However, whether NO directly regulates vascular endothelial cell (EC) insulin uptake and its transendothelial transport (TET) is unknown. We report in this article that l-NG-nitro-l-arginine methyl ester (l-NAME) pretreatment blocked, whereas l-arginine and sodium nitroprusside (SNP) each enhanced, EC uptake of fluorescein isothiocyanate (FITC)-labeled insulin. SNP also partly or fully reversed the inhibition of EC insulin uptake caused by l-NAME, wortmannin, the Src inhibitor PP1, and tumor necrosis factor-α. In addition, SNP promoted [125I]TyrA14insulin TET by ∼40%. Treatment with insulin with and without SNP did not affect EC cyclic guanosine monophosphate (cGMP) levels, and the cGMP analog 8-bromo-cGMP did not affect FITC-insulin uptake. In contrast, treatment with insulin and SNP significantly increased EC protein S-nitrosylation, the colocalization of S-nitrosothiol (S-NO) and protein-tyrosine phosphatase 1B (PTP1B), and Akt phosphorylation at Ser473 and inhibited PTP1B activity. Moreover, a high-fat diet significantly inhibited EC insulin-stimulated Akt phosphorylation and FITC-insulin uptake that was partially reversed by SNP in rats. Finally, inhibition of S-nitrosylation by knockdown of thioredoxin-interacting protein completely eliminated SNP-enhanced FITC-insulin uptake. We conclude that NO directly promotes EC insulin transport by enhancing protein S-nitrosylation. NO also inhibits PTP1B activity, thereby enhancing insulin signaling.
Before insulin can act on myocytes, it must first traverse the continuous vascular endothelium in skeletal muscle. Insulin delivery to muscle is affected by blood flow (1), flow distribution (2), and insulin transendothelial transport (TET) (3,4). Importantly, insulin delivery to muscle interstitial fluid is a rate-limiting step in the peripheral action of insulin (5,6) and is delayed in insulin-resistant, obese humans, suggesting a significant role for this transport process in peripheral insulin resistance (7,8). Endothelial dysfunction, secondary to reduced nitric oxide (NO) bioavailability, is an early and prominent feature of insulin resistance. Endothelial NO synthase (NOS-3 or eNOS) produces NO from l-arginine, and eNOS is activated by insulin at physiologic concentrations. Knockout of eNOS or inhibiting insulin signaling by endothelium-specific knockout of IRS2, leading to the reduction of eNOS activity in the vascular endothelial cell (EC), produces metabolic insulin resistance (9,26). In addition, endothelial-specific knockout of IRS2 inhibits insulin-induced microvascular recruitment and reduces insulin delivery to muscle interstitium. However, it is not known whether the reduced insulin delivery is a result of reduced blood flow, altered flow distribution, impaired insulin TET, or a combination of these (26). We and others have previously shown that insulin induces vasodilation by enhancing NO production to facilitate its own delivery to the peripheral tissues in vivo (1,2). Whether NO directly affects insulin uptake and TET has not been examined.
The insulin receptor and caveolae mediate EC insulin uptake (4,11–13), and this process is blunted by either inhibiting intracellular insulin signaling or treating with tumor necrosis factor-α (TNF-α). Conversely, stimulating intracellular insulin signaling by inhibiting protein-tyrosine phosphatase 1B (PTP1B) enhances insulin uptake (12).
In the current study, we found that exogenously delivered NO stimulated both the uptake and the TET of insulin by aortic ECs. We also found that NO partially or fully restored insulin uptake by the cells pretreated with inhibitors of insulin signaling pathways (12). To explain these findings, we examined pathways downstream of NO production by which the NO might act on insulin uptake. We found that exogenously delivered NO can directly promote insulin transport independent of eNOS activity through enhancing protein S-nitrosylation, including that of PTP1B, without affecting the soluble guanylyl cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway and overcome the impaired insulin transport seen with experimental insulin resistance.
RESEARCH DESIGN AND METHODS
Bovine aorta ECs (bAECs) (passage numbers 2–8; BioWhittaker, Inc., Walkersville, MD) were grown in microvascular endothelial cell growth medium.
Measurement of insulin TET.
These experiments were performed as previously described (4,14). Briefly, bAECs were seeded onto Transwell inserts (6.5 mm diameter, 0.4 μm pore size, polyester membrane) (Corning Incorporated, Corning, NY) treated with human fibronectin (Sigma-Aldrich, St. Louis, MO). The transendothelial electrical resistances were monitored daily with an Epithelial Voltohmmeter and EndOhm chamber (WPI, Sarasota, FL). After the transendothelial electrical resistance reached a plateau, the endothelial monolayers were washed twice at 37°C with endothelial basal medium (EBM), and the fluid in the top chamber was replaced with EBM containing [125I]TyrA14insulin (125I-insulin) 200 pmol/L (PerkinElmer, Boston, MA) with or without 0.3 μmol/L sodium nitroprusside (SNP) (Calbiochem). At selected times, 200 μL fluid was removed from the bottom chamber and replaced with 200 μL EBM to ensure hydrostatic balance. The concentration of 125I-insulin was measured with a γ counter. The percentage of insulin transported was calculated.
Adult male Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA) were housed in an animal room maintained at ∼22°C with a 12-h light/dark cycle and fed ad libitum. Rats were randomly assigned to either a high-fat diet (HFD) (60% fat, 20% protein, 20% carbohydrate) (product number D12492; Research Diets, New Brunswick, NJ) or a control regular chow diet (product number 7012; Harlan Laboratories) for 4 weeks. Rats were killed by CO2. The aorta was quickly dissected and put into 5% CO2 in O2-bubbled modified Krebs buffer (NaCl 119 mmol/L, KCl 4.7 mmol/L, CaCl2⋅2H2O 2.5 mmol/L, MgSO47H2O 1.17 mmol/L, NaHCO3 25 mmol/L, KH2PO4 1.18 mmol/L, EDTA 0.027 mmol/L, glucose 5.5 mmol/L). The surrounding fascia was carefully removed, and the vessel was divided into small segments and cut open. After stabilization in a cell culture incubator for 1 h, these aortic segments were treated with 0.3 or 30 μmol/L SNP with or without 50 nmol/L fluorescein isothiocyanate (FITC)-labeled insulin (Sigma-Aldrich) or regular insulin for 30 min. After fixation with cold methanol, the endothelial face of the vessel was placed face down onto a coverslip that was precoated with poly-l-lysine (Sigma-Aldrich), pressure was applied briefly, the vessel wall was removed, and the coverslip with adherent ECs was processed for immunocytochemical staining (see immunocytochemistry). The study procedure was approved by the animal care and use committee of the University of Virginia.
Western blotting was performed as described previously (13,15). Briefly, after blocking with 5% low-fat milk in Tris-buffered saline (TBS) plus Tween 20, membranes were incubated overnight at 4°C with monoclonal antibody against thioredoxin-interacting protein (Txnip) (MBL International Corporation, Woburn, MA), polyclonal antibody against caveolin-1 (Santa Cruz Biotechnology, Santa Cruz, CA), or monoclonal antibody against GAPDH (Sigma-Aldrich). This procedure was followed by incubation with a species-specific secondary antibody coupled to horseradish peroxidase (Amersham [GE Healthcare Life Sciences], Piscataway, NJ), and the blots were developed with an enhanced chemiluminescence Western blotting kit (Amersham [GE Healthcare Life Sciences]). The developed films were scanned with a densitometer (Molecular Dynamics, Amersham, Piscataway, NJ) and quantified with the use of ImageQuant 5.0 software.
Real-time RT-PCR assay was performed as described previously (13,14). Briefly, total RNAs were extracted from the cultured bAECs with an RNeasy kit (Qiagen) and were reverse transcribed with the iScript cDNA synthesis kit (Bio-Rad). The cDNA products were then amplified with iQ SYBR Green Supermix on an iCycler apparatus (Bio-Rad). For the amplification of Txnip gene products, the following primers were designed: forward 5′-CATGTGGAGGAGAGCCAATTTA-3′ and reverse 5′-GCCCAGTTACTACTGCCTTATG-3′, and the Txnip mRNA levels were normalized to the housekeeping gene (GAPDH) mRNAs (primers designed: forward 5′-GGGTCATCATCTCTGCACCT-3′ and reverse 5′-GGTCATAAGTCCCTCCACGA-3′) (Integrated DNA Technologies, Coralville, IA). Standard curves for each mRNA were generated by serial dilution of cDNA synthesized from the extracted total RNA and was included in each iCycler real-time RT-PCR experiment. The specificity of the desired product was verified by analysis of the melting curve.
Small interfering RNA design and transfection.
A specific small interfering RNA (siRNA) duplex against bovine Txnip mRNA and a scrambled siRNA control were purchased from Dharmacon, Inc. (Lafayette, CO). Cells were seeded and transfected when they reached 30–50% confluency with siRNA duplex to a final concentration of 40 nmol/L with use of Oligofectamine (Invitrogen, Carlsbad, CA). Forty-eight hours after transfection, cells were serum starved for 6 h followed by insulin treatment as described previously (13,14).
The double-staining protocols were the same as described previously (4,12). Briefly, the methanol-fixed bAECs were washed three times in TBS, permeabilized in TBS containing 0.05% Triton X-100 and 1% horse or goat serum for 30 min at room temperature, and incubated with two different primary antibodies against two different target proteins (double labeling) overnight at 4°C. The following primary antibodies were used: rabbit polyclonal anti-FITC (Molecular Probes, Inc., Eugene, OR), mouse monoclonal anti-Txnip (MBL International Corporation), monoclonal anti-PTP1B (Abcam, Cambridge, MA), and monoclonal antiphospho-Akt (Ser473) (Millipore). The cells were washed three times in TBS and then incubated with species-specific secondary antibodies conjugated with a fluorochrome cyanine (Cy2 or Cy3) (Jackson ImmunoResearch, West Grove, PA) at 1:200 dilutions for 45 min at room temperature. The cells were washed three times in TBS and then coverslipped with antifade mounting medium with DAPI.
Assay for cGMP.
Intracellular cGMP concentration of the cultured bAECs was measured with a cGMP enzyme immunosorbent assay kit (Cayman Chemical). The sensitivity of the assay was enhanced by the optional acetylation procedure according to the manufacturer’s protocol. Cells were treated with or without isobutylmethylxanthine 200 μmol/L (Sigma-Aldrich) for 10 min before insulin and/or SNP stimulation. Protein concentration was measured by the Bradford method. The measured cGMP values were normalized against the corresponding protein concentrations.
Rat’s blood analyses.
Arterial serum glucose concentrations were measured with a glucose colorimetric assay kit (Cayman Chemical). Serum insulin (Mercodia AB, Uppsala, Sweden) and triglyceride (Cayman Chemical) concentrations were measured with ELISA.
In situ detection of PTP1B S-nitrosylation.
The general protein S-nitrosylation in the ECs harvested from rat aortas (see previous discussion) was evaluated in situ with the use of the biotin-switch technology–based S-Nitrosylated Protein Detection Assay Kit (Cayman Chemical) according to the manufacturer’s protocol. The biotin derivatization was detected by the included fluorescein-conjugated avidin. In these experiments, assay of the protein S-nitrosylation was determined in combination with the immunocytochemical staining for PTP1B with the monoclonal primary antibody against PTP1B followed by a species-specific secondary antibody conjugated with Cy3 and visualized by confocal imaging.
PTP1B enzymatic activity assay.
The PTP1B activity of bAECs was measured after precipitation of PTP1B with a modified immunoprecipitation procedure described previously (15,16). Briefly, cultured bAECs were scraped in ice-cold lysis buffer (PBS containing 1% NP-40, 1% deoxycholate, 5 mmol/L EDTA, 1 mmol/L EGTA, 2 mmol/L phenylmethylsulfonyl fluoride, and 0.1 mmol/L leupeptin). The lysates were gently rocked at 4°C for 15 min and then centrifuged at 14,000g for 10 min at 4°C. The supernatants were precleared by adding 20 μL/mL cell lysate protein A/G plus agarose (Santa Cruz Biotechnology) at 4°C for 10 min. Equal amounts of protein samples (500 μg of total protein) were immunoprecipitated with the monoclonal anti-PTP1B antibody at 4°C overnight. PTP1B immunocomplexes were further precipitated by the protein A/G plus agarose at 4°C for an additional 2 h. Immunoprecipitates were washed five times with TBS, and the residue TBS buffer was removed. The activity of purified PTP1B was assayed with a PTP1B assay kit (Calbiochem) according to the manufacturer’s protocol. Briefly, the phosphopeptide substrate IR5 (containing a sequence from the insulin receptor β subunit domain that must be autophosphorylated to achieve full receptor kinase activation) was added to a final concentration of 75 μmol/L in a total reaction volume of 100 μL in the assay buffer. The sample mixtures were incubated for 30 min at 30°C. After the reaction, 60-μL aliquots were placed into half-area 96-well plates, and 25 μL red reagent plus 40 μL assay buffer were added to each sample well and gently mixed. After incubation at room temperature for 30 min, the absorbance was measured at 620 nm with a plate reader.
The immunocytochemical labeling was examined with a confocal microscope as described previously (4,12–15). Confocal imaging was performed with a Leica SP5 X imaging system equipped with ultraviolet (405 nm), tunable (470–670 nm) white light and argon ion lasers (458, 477, 488, 496, 514 nm); ×40 and ×60 1.4 numerical aperture oil-immersion lenses were used to acquire optical sections. During image acquisition, the individual microscopic field was selected to include a similar number of cells but was otherwise random. To quantify fluorescence intensity, the images from randomly selected microscopic fields containing a similar number of nuclei staining were outlined, and the integrated fluorescence intensities were measured with Image J software. In the case (Fig. 5A) where only a few cells were included in each microscopic field, as the protocol for the S-nitrosylated protein detection assay kit requires use of 4% paraformaldehyde with the specific wash buffer for cell fixation, which appeared to inhibit intact rat ECs attachment to the coverslip, individual cells were outlined by polygonal method (30 cells for each group were randomly selected), and the integrated fluorescence intensities were measured. Digital images were processed identically with Adobe Photoshop.
Data are presented as mean ± SEM. Statistical comparisons among different groups were made with one-way ANOVA with Student-Newman-Keuls post hoc testing. Statistical significance is defined as P ≤ 0.05.
NO production regulates FITC-insulin uptake.
We first examined the effect of l-NG-nitro-l-arginine methyl ester (l-NAME) inhibition of NOS on FITC-insulin uptake. Figure 1A shows that compared with control, pretreating bAECs with l-NAME strongly inhibited FITC-insulin uptake (P < 0.05). Conversely, pretreatment of bAECs with 500 μmol/L l-arginine (the substrate of eNOS) for 30 min significantly increased FITC-insulin uptake (Fig. 1B and D), whereas pretreatment of cells with d-arginine had no effect. l-NAME added with l-arginine blocked the increased uptake seen with l-arginine alone (Fig. 1B and D). We then examined whether the effect of l-arginine on FITC-insulin uptake could be mimicked by giving NO to bAECs. Adding modest concentrations (0.01∼0.3 μmol/L) of SNP, an NO donor, significantly increased FITC-insulin uptake by bAECs compared with FITC-insulin alone (P < 0.05) (Fig. 1C and D) (also see Fig. 6F and H). However, SNP at higher concentrations did not stimulate insulin uptake (Fig. 1C), suggesting a biphasic action with an inhibitory effect of higher SNP (NO) concentrations (17–19). Of note, 0.3 μmol/L SNP also eliminated the inhibitory effect of l-NAME on FITC-insulin uptake (Fig. 1A and E).
Next, we examined the effect of SNP on 125I-insulin TET with a Transwell device (4,14). Figure 2 shows that compared with control, adding SNP increased 125I-insulin TET by ∼40% at both 10 and 60 min (P < 0.05 for each time point). In aggregate, these data suggest that the NO donor SNP may directly promote insulin transport in an eNOS activity-independent fashion.
NO rescues the inhibition of insulin uptake induced by blocking intracellular insulin signaling pathways.
We previously reported that insulin transport by bAECs depends on its intracellular insulin signaling as either general inhibition of tyrosine kinases (genistein) or more-specific inhibition of Src (PP1), phosphatidyl-inositol-3 kinase (PI3K) (wortmannin), or mitogen-activated protein kinase (MAPK) (PD 098059) (12); each inhibited FITC-insulin uptake. Therefore, we tested whether adding SNP to bAECs relieved the inhibition of FITC-insulin uptake induced by blocking these intracellular insulin signaling pathways. Figure 3 and Supplementary Fig. 1 show that pretreatment of bAECs with wortmannin, genistein, PP1, or PD 098059 significantly inhibited FITC-insulin uptake as reported previously (12). Adding SNP, however, completely rescued both wortmannin- and PP1-inhibited insulin uptake (Fig. 3A–C) and partially restored FITC-insulin uptake that had been inhibited by PD 098059 (Supplementary Fig. 1B). SNP did not significantly affect genistein-inhibited FITC-insulin uptake (Supplementary Fig. 1A). These data indicate that NO is able to promote FITC-insulin uptake despite preinhibiting some intracellular insulin signaling pathways.
We previously used TNF-α treatment of ECs as an in vitro model of insulin resistance and showed that treatment of bAECs with TNF-α inhibited FITC-insulin uptake (12). Figure 3D shows that adding 0.3 μmol/L SNP not only completely rescued TNF-α–induced inhibition of insulin uptake but strikingly stimulated FITC-insulin uptake.
SNP-enhanced insulin transport requires protein S-nitrosylation but not activation of sGC.
We next examined the pathways by which SNP promoted FITC-insulin transport. The selective, irreversible, heme-site inhibitor of sGC 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) (20) completely eliminated the enhanced FITC-insulin uptake induced by SNP compared with vehicle control (Fig. 4A and C). However, the membrane-permeable cGMP analog 8-bromo-cGMP over a range of concentrations had no significant effects on FITC-insulin uptake (Fig. 4B). In addition, treatment of ECs with insulin with or without SNP did not significantly affect the intracellular cGMP levels (Supplementary Fig. 2), which is consistent with a previous report (21). This seeming inconsistency may be explained by the observation that to exert its biological effects as an NO donor, higher concentrations of SNP (>30 nmol/L) require intracellular bioactivation (metabolic NO formation) that is susceptible to inhibition by ODQ (22). In aggregate, these data suggest that SNP-enhanced insulin transport may not be mediated by activation of sGC.
Because NO also regulates cellular function by S-nitrosylation, we next examined the effect of SNP treatment on protein S-nitrosylation. Figure 5A (top row) and B show that both insulin and SNP treatment increased the protein S-nitrosylation level, and SNP plus insulin treatment further significantly increased the protein S-nitrosylation compared with either insulin or SNP alone in the intact aortic ECs of rats ex vivo. Because the steady-state level of protein S-nitrosylation is determined by the balance between nitrosylation and denitrosylation, thioredoxin activity (a broad-spectrum denitrosylase) is important for determining the steady-state levels of protein S-nitrosylation (23). Txnip has been demonstrated to critically inhibit protein denitrosylation (19). To examine the effect of reducing S-nitrosylation on SNP-stimulated FITC-insulin uptake, we designed a specific siRNA against Txnip in bAECs to silence Txnip expression and thereby promote protein denitrosylation. Figure 6A and B show that compared with the scrambled siRNA, the siRNA against Txnip reduced Txnip protein expression by ∼75%. Neither caveolin-1 nor GAPDH protein expression was affected by knockdown of Txnip. Figure 6C–H show that insulin significantly increased Txnip staining compared with the basal medium control (P < 0.05), and 0.3 μmol/L SNP plus insulin further increased Txnip staining compared with insulin alone (P < 0.05) (Fig. 6C, E–G, and I) both in vitro and ex vivo, although a higher SNP dose (30 μmol/L) had no additional effect on Txnip staining (Fig. 6F, G, and I). Of note, the increased Txnip staining induced by insulin or insulin plus 0.3 μmol/L SNP was paralleled by enhanced protein S-nitrosylation (Fig. 5A [top row] and B). On the other hand, insulin with or without 0.3 μmol/L SNP treatment did not affect Txnip mRNA expression (P > 0.05) (Fig. 6J), suggesting that these treatments inhibit the rapid turnover of Txnip proteins, leading to an enhanced protein S-nitrosylation (19). Additionally, compared with the scrambled siRNA control, knockdown of Txnip with the specific siRNA against Txnip (Fig. 6C [right] and E) strikingly reduced SNP-promoted FITC-insulin uptake (Fig. 6C [left] and D) proportionately to the reduced level of Txnip found (Fig. 6C [right] and E). These data indicate that NO may have promoted insulin transport not through activation of sGC but through promotion of protein S-nitrosylation.
Because we previously reported that inhibition of PTP1B with a specific PTP1B inhibitor significantly enhanced FITC-insulin uptake by aortic ECs (12), we next examined whether treatment of aortic ECs with insulin and/or 0.3 μmol/L SNP affected the S-nitrosylation of PTP1B and its enzymatic activity. Figure 5A shows that although 0.3 μmol/L SNP- or insulin-only treatment increased PTP1B protein S-nitrosylation, 0.3 μmol/L SNP plus insulin treatment caused the most robust PTP1B protein S-nitrosylation as indicated by almost complete colocalization of S-NO and PTP1B (Fig. 5A [bottom row]) compared with the basal medium control. In addition, vehicle plus insulin treatment tended to inhibit PTP1B activity, but it was not statistically significant; however, 0.3 μmol/L SNP plus insulin treatment almost completely inhibited PTP1B activity (P < 0.05) compared with either basal medium or vehicle plus insulin controls (Fig. 5C). These data suggest that NO may inhibit PTP1B activity through S-nitrosylation of PTP1B protein to regulate insulin transport.
NO stimulates intracellular insulin signaling and reverses HFD-induced impairments in insulin signaling and uptake in Sprague-Dawley rats.
Finally, we examined the effects of NO on intracellular insulin signaling by in situ detection of changes in Akt phosphorylation at Ser473, using fresh rat aortic ECs attached to coverslips. Because high-fat feeding of rats for 3∼4 weeks has been shown to cause whole-body insulin resistance and vascular dysfunction (24,25), we also examined the effects of feeding rats an HFD for 4 weeks on vascular endothelial insulin signaling and uptake and responsiveness to SNP. Supplementary Fig. 3A–D show that although serum glucose concentrations were not changed, body weight and serum triglyceride and insulin levels were increased by HFD feeding consistent with a state of insulin resistance as previously reported (24,25). In the rats on the regular chow diet, 0.3 μmol/L SNP significantly increased insulin-stimulated Akt phosphorylation at Ser473 and FITC-insulin uptake (Fig. 7). In addition, 4 weeks of HFD feeding inhibited both FITC-insulin uptake and insulin-stimulated Akt phosphorylation at Ser473, and 0.3 μmol/L SNP treatment partially but significantly reversed both effects (Fig. 7). These data combined with those shown in Fig. 5 suggest that NO may enhance EC insulin signaling and uptake in part through inhibition of PTP1B activity (Fig. 8).
To our knowledge, the results provide the first demonstration that NO can directly promote both insulin uptake and TET by arterial ECs. Furthermore, NO (SNP, an NO donor) can completely or partially restore insulin uptake that was inhibited by agents that interfere with signaling through PI3K, Src, or MAPK as well as by TNF-α and high-fat feeding in vivo. SNP did not reverse the inhibition of insulin uptake provoked by genistein, a nonspecific tyrosine kinase inhibitor. Although NO exerts its diverse cellular actions through enhancing both sGC-cGMP-protein kinase G– and protein S-nitrosylation–mediated signaling pathways, the present data support an important role for the latter pathway in mediating NO-stimulated insulin uptake and transport. Taken together, the current results indicate a third role for NO related to facilitating insulin delivery to muscle tissue. This action, coupled with its vasodilatory actions to increase muscle blood flow (1) and improve flow distribution (2,26), suggests a highly coordinated physiological role for NO to promote insulin delivery.
In the current study, we found that pretreatment of bAECs with l-NAME 100 μmol/L completely inhibits FITC-insulin uptake and that SNP can overcome the inhibition induced by l-NAME, suggesting that the exogenous NO from SNP is enough to enhance insulin uptake regardless of endogenous NO production. Insulin clamp studies have shown that the eNOS−/− mouse is metabolically insulin resistant (9), and an in vivo study showed that these mice manifest increased inflammation and impaired insulin signaling in aortic tissues (27).
Previous in vivo studies showed that insulin delivery from the plasma to the interstitial fluid compartment of skeletal muscle is a rate-limiting step in the peripheral action of insulin (5,6). This process is delayed in insulin-resistant, obese subjects in whom a significantly lower interstitial insulin level is seen in the early phase of insulin infusion compared with normal control subjects (7,8,26). Whether the delayed interstitial delivery of insulin in insulin-resistant, obese subjects is due to a defective vasodilating response, a lower capillary density (8,26,28,29), a defective TET (3,4,11), or a combination of these is uncertain. To dissect the effects of NO specifically on insulin TET, we used a Transwell device on which a confluent bAEC monolayer mimics the endothelial boundary in the vasculature of peripheral tissues, such as muscle and adipose tissues. Previous in vitro studies by us and others used this approach and demonstrated that insulin TET is receptor mediated (3,4) and involves caveolae (11,13). This receptor-mediated process is regulated by intracellular insulin signaling (12,14). In the current study, we observed that NO acts directly on vascular ECs to promote insulin uptake and TET.
Endothelial dysfunction, characterized by a deficiency of bioavailable NO, has been found to precede the development of type 2 diabetes and is significantly correlated with insulin resistance (30). Endothelial NO production has been shown to be positively related to peripheral insulin sensitivity (31). Insulin itself is an important eNOS activator (32). Inhibiting insulin signaling inhibits insulin uptake and TET in vitro (12,14) and insulin transcapillary transport in vivo (26). In the current study, we observed that SNP partially or completely relieves the inhibition of insulin uptake provoked by wortmannin, PD 098059, and PP1 but not that caused by genistein. Another study reported that an NO donor can directly activate PI3K and MAPK signaling pathways in both human and rat vascular smooth muscle cells (33). On the other hand, TNF-α decreases EC NO bioavailability (34) by inhibiting eNOS expression and interfering with early events in insulin signaling (35,36) and inhibits insulin uptake by bovine aortic ECs (12). In the current study, we observed that SNP eliminates the TNF-α inhibition of insulin uptake and even enhances insulin uptake beyond that seen in control cells (Fig. 3D and E). The NO donor diethylenetriamine/nitric oxide was reported to rescue the palmitate-induced inhibition of insulin-stimulated IRS1, Akt, and eNOS phosphorylation in human umbilical vein ECs, whereas knockout of eNOS in vivo increased the vascular inflammation and insulin resistance (27).
The rat on an HFD for 4 weeks provides a well-characterized insulin resistance model. HFD feeding for 4 weeks induces vascular insulin resistance characterized by loss of insulin-mediated microvascular perfusion in skeletal muscle and whole-body and muscle metabolic insulin resistance (24,25). Of note, HFD-fed mice demonstrate impaired intracellular insulin signaling in aortic tissue much earlier (within 1 week of HFD feeding) than that in liver, muscle, and adipose tissues (37). In the current study, we show that both insulin-stimulated Akt phosphorylation and insulin uptake are suppressed in aortic ECs from the rats fed an HFD for 4 weeks (Fig. 7). Treatment with 0.3 μmol/L SNP could inhibit PTP1B activity (Fig. 5A and C) and enhance intracellular insulin signaling and partially reverse the HFD-induced impairments in both insulin signaling and insulin uptake.
NO regulation of cellular function is complex (38,39) and appears to involve at least two major mechanisms under physiological conditions: 1) activation of sGC (38) and 2) reversible posttranslational modification of proteins by S-nitrosylation (or for some proteins, S-nitrosylation could be an intermediate step leading to the glutathionylation that also regulates protein function) (40). S-nitrosylation has emerged as an important feature of NO signaling (39). Indeed, we observed that SNP treatment significantly increases in situ protein S-nitrosylation in intact aortic ECs ex vivo (Fig. 5). In addition, we observed that the intracellular cGMP levels in cultured bAECs are barely detectable, even after preinhibition of the intracellular cGMP phosphodiesterase with isobutylmethylxanthine. Furthermore, cGMP levels are not changed after stimulation with insulin, SNP, or both, which is consistent with findings reported by others (21). These results combined with the failure of 8-bromo-cGMP to stimulate insulin uptake suggest that in vascular ECs, enhanced cGMP generation is not necessary for SNP (or NO)-stimulated insulin uptake. This finding led us to explore whether SNP-stimulated insulin uptake might be acting through protein S-nitrosylation. To address this, we took advantage of the fact that Txnip inhibits thioredoxin (a broad-spectrum denitrosylase) and that cellular Txnip protein turnover is very fast (half-life 10–20 min) (19). By decreasing Txnip, siRNA directed against Txnip would be expected to enhance thioredoxin-mediated reduction of protein S-nitrosylation and in the current context, to diminish SNP-stimulated insulin uptake. Of note, in contrast to the results observed previously with either high concentrations of NO donor (≥10 μmol/L S-nitrosoglutathione) (18) or endogenously produced NO through the activation of inducible NOS by cytokine stimulation (19) in which the higher concentration of NO actually inhibited Txnip expression, we observed in the present study that adding insulin modestly, but significantly (P < 0.05), increased Txnip staining (i.e., enhanced protein S-nitrosylation) and that adding low concentrations of SNP with insulin further enhanced Txnip staining (Fig. 6C [right], E, F [top row], G, and I and Fig. 5A and B) and corresponded to a significant increase in insulin uptake (Fig. 6C [left], D, F [middle row], and H). In addition, the mRNA of Txnip expression was not affected by these treatments (Fig. 6J), suggesting that these treatments may have attenuated the rapid turnover of Txnip (19). Conversely, knockdown of Txnip (which would be expected to reduce protein S-nitrosylation) (Fig. 6C [right] and E) reduced insulin uptake (Fig. 6C [left] and D). These data indicate that the NO-mediated protein S-nitrosylation plays a critical role in the regulation of insulin uptake.
The mechanism by which protein S-nitrosylation regulates insulin uptake is not clear. PTP1B plays a critical role in the inhibition of intracellular insulin signaling. Insulin signaling begins with tyrosine phosphorylation of the insulin receptor and subsequent tyrosine phosphorylation of its primary substrates, the IRS proteins. PTP1B dephosphorylates these proteins to reduce their activity. In this way, intracellular insulin signaling is balanced. Increasing evidence demonstrates that PTP1B activity under normal metabolic conditions is tightly regulated by oxidation/reduction reactions, including S-nitrosylation/denitrosylation involving the cysteine thiol moiety required for catalysis (41). Moreover, studies by us and others (12,14,26) have demonstrated that inhibiting insulin signaling significantly reduces insulin transport, whereas enhancing insulin signaling by inhibition of PTP1B significantly increases insulin uptake (12). In the current study, we used an in situ detection of protein S-nitrosylation combined with the immunohistochemical staining for PTP1B in ECs freshly harvested from rat aorta and found that NO not only increases protein S-nitrosylation, but also increases the colocalization of S-NO and PTP1B as well as enhances insulin-stimulated Akt phosphorylation at Ser473, a marker for enhanced insulin signaling through the IRS1/2-PI3K-Akt pathway. We also noted that cotreatment with SNP and insulin inhibits PTP1B activity in cultured aortic ECs. These new findings, combined with our previous report (12) that the inhibition of PTP1B enhances insulin uptake, indicate that the effects of NO observed in the present study may be mediated, at least in part, by the inactivation of PTP1B possibly through its S-nitrosylation (Fig. 8). The ability of NO to completely restore insulin uptake that had been inhibited by the Src kinase inhibitor PP1 is consistent with this hypothesis because Src activity is tightly regulated by PTP1B (41). Further studies are warranted to thoroughly clarify this complex mechanism. Taken together, the current data suggest that several pathways of NO-regulated signaling are required for NO-stimulated insulin uptake.
In summary, we report what we believe to be the first observations that NO can directly act on arterial ECs to promote insulin uptake and TET under both physiological and pathophysiological conditions. Beyond that, the findings suggest a significant role for protein S-nitrosylation in the action of NO on insulin uptake and transport. Inhibition of PTP1B possibly induced by its S-nitrosylation appears to significantly contribute to NO-stimulated endothelial insulin uptake and transport.
This work was supported by research grants from the National Institutes of Health (DK-057878 and DK-073059) and American Diabetes Association (11-BS6) to E.J.B.
No potential conflicts of interest relevant to this article were reported.
H.W. designed the study, conducted the experiments, performed the data analyses, and wrote the manuscript. A.X.W. and K.A. conducted the experiments. E.J.B. contributed to the discussion and reviewed and edited the manuscript. H.W. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Parts of this study were presented in abstract form at the 73rd Scientific Sessions of the American Diabetes Association, Chicago, Illinois, 21–25 June 2013.
This article contains Supplementary Data online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-0627/-/DC1.
See accompanying commentary, p. 4006.
- Received April 22, 2013.
- Accepted July 9, 2013.
- © 2013 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.